STOCK TITAN
  1. Home
  2. Sec-filings
  3. ETON
  4. [8-K] Eton Pharmaceuticals, Inc. Reports Material Event

Eton Pharmaceuticals (NASDAQ: ETON) 2026 vote supports board and auditor

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Eton Pharmaceuticals, Inc. held its 2026 Annual Meeting of Stockholders virtually on June 9, 2026. Stockholders elected Jenn Adams and Charles J. Casamento to the board for three-year terms and ratified Grant Thornton LLP as independent registered public accounting firm for the year ending December 31, 2026.

Positive

  • None.

Negative

  • None.
Item 5.07 Submission of Matters to a Vote of Security Holders Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Votes for Jenn Adams 13,370,948 votes Election of director at 2026 Annual Meeting
Votes withheld Jenn Adams 2,149,317 votes Election of director at 2026 Annual Meeting
Votes for Charles J. Casamento 9,925,548 votes Election of director at 2026 Annual Meeting
Votes withheld Charles J. Casamento 5,594,717 votes Election of director at 2026 Annual Meeting
Broker non-votes (directors) 4,664,035 votes Both director election proposals
Votes for auditor ratification 16,942,328 votes Ratification of Grant Thornton LLP for 2026
Votes against auditor ratification 3,236,671 votes Ratification of Grant Thornton LLP for 2026
Abstain on auditor ratification 5,301 votes Ratification of Grant Thornton LLP for 2026
broker non-votes financial
"Nominee | For | Withheld | Broker Non-Votes Jenn Adams | 13,370,948 | 2,149,317 | 4,664,035"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
independent registered public accounting firm financial
"ratified the appointment of Grant Thornton LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026"
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
Annual Meeting of Stockholders financial
"The 2026 Annual Meeting of Stockholders (the “Annual Meeting”) of Eton Pharmaceuticals, Inc. was held virtually on June 9, 2026"
emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →
false 0001710340 0001710340 2026-06-09 2026-06-09
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM 8-K
 
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
June 9, 2026
Date of Report (Date of earliest event reported)
 
 
ETON PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
 
Delaware
001-38738
37-1858472
(State of
(Commission
(I.R.S. Employer
incorporation)
File Number)
Identification Number)
 
21925 W. Field Parkway, Suite 235
Deer Park, Illinois 60010-7278
(Address of principal executive offices) (Zip code)
 
(847) 787-7361
(Registrant’s telephone number, including area code)
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
 
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
 
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
 
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
  
Trading symbol(s)
  
Name of each exchange on which registered
Common Stock, par value $0.001 per share
  
ETON
  
NASDAQ Global Market
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
 
 
 
Item 5.07.  Submission of Matters to a Vote of Security Holders
 
The 2026 Annual Meeting of Stockholders (the “Annual Meeting”) of Eton Pharmaceuticals, Inc. (the “Company”) was held virtually on June 9, 2026. At the meeting, the Company’s stockholders (1) elected the director nominees Jenn Adams and Charles J. Casamento for a three-year term and (2) ratified the appointment of Grant Thornton LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026.
 
The results for each of the matters voted upon by the Company’s stockholders at the Annual Meeting were as follows:
 
Proposal 1: Election of Directors
 
Nominee
For
Withheld
Broker Non-Votes
Jenn Adams
13,370,948
 2,149,317 4,664,035
Charles J. Casamento 9,925,548 5,594,717 4,664,035
 
Proposal 2: Ratification of the Appointment of Grant Thornton LLP as the Company’s Independent Registered Public Accounting Firm for the year ending December 31, 2026
 
For
Against
Abstain
16,942,328
 3,236,671 5,301
 
 
2
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
Date: June 9, 2026
By:
/s/ Judith Matthews
   
Judith Matthews
   
Chief Financial Officer and Secretary
   
(Principal Financial Officer)
 
3

Source: View Original Filing on SEC EDGAR

FAQ

What did ETON stockholders approve at the 2026 annual meeting?

ETON stockholders elected Jenn Adams and Charles J. Casamento to three-year board terms and ratified Grant Thornton LLP as independent auditor for the year ending December 31, 2026. Both proposals received majority support from votes cast at the virtual meeting.

How did ETON stockholders vote on director Jenn Adams?

Jenn Adams received 13,370,948 votes for election and 2,149,317 votes withheld, with 4,664,035 broker non-votes. This indicates strong support from voting stockholders for her continued service as a director on Eton Pharmaceuticals’ board.

What were the voting results for director Charles J. Casamento at ETON?

Charles J. Casamento received 9,925,548 votes for election and 5,594,717 votes withheld, plus 4,664,035 broker non-votes. While he faced more withheld votes than Jenn Adams, the support remained sufficient for election to a three-year board term.

Did ETON stockholders ratify Grant Thornton LLP as auditor for 2026?

Yes. Stockholders cast 16,942,328 votes for ratifying Grant Thornton LLP as Eton Pharmaceuticals’ independent registered public accounting firm for 2026, with 3,236,671 votes against and 5,301 abstentions, confirming continued engagement of the same external audit firm.

When and how was ETON’s 2026 annual meeting held?

Eton Pharmaceuticals held its 2026 Annual Meeting of Stockholders virtually on June 9, 2026. Stockholders participated remotely to vote on the election of two directors and the ratification of Grant Thornton LLP as the company’s independent registered public accounting firm.

Filing Exhibits & Attachments

4 documents

Other Documents